Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment

IMPORTANCE: The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure. OBJECTIVE: To assess the short-term psychological outcomes of disclosing amyloid positron emission tomography r...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Neurol
Autores principales: Grill, Joshua D., Raman, Rema, Ernstrom, Karin, Sultzer, David L., Burns, Jeffrey M., Donohue, Michael C., Johnson, Keith A., Aisen, Paul S., Sperling, Reisa A., Karlawish, Jason
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418046/
https://ncbi.nlm.nih.gov/pubmed/32777010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.2734
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares